- Home
- PYPD vs CELU Comparison
PYPD vs CELU Comparison
Compare PYPD & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- CELU
- Stock Information
- Founded
- PYPD 2008
- CELU 2016
- Country
- PYPD Israel
- CELU United States
- Employees
- PYPD N/A
- CELU N/A
- Industry
- PYPD Medical/Dental Instruments
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- PYPD Health Care
- CELU Health Care
- Exchange
- PYPD Nasdaq
- CELU Nasdaq
- Market Cap
- PYPD 36.0M
- CELU 42.2M
- IPO Year
- PYPD 2020
- CELU N/A
- Fundamental
- Price
- PYPD $3.66
- CELU $3.03
- Analyst Decision
- PYPD Strong Buy
- CELU
- Analyst Count
- PYPD 5
- CELU 0
- Target Price
- PYPD $11.40
- CELU N/A
- AVG Volume (30 Days)
- PYPD 175.1K
- CELU 491.2K
- Earning Date
- PYPD 08-13-2025
- CELU 05-08-2025
- Dividend Yield
- PYPD N/A
- CELU N/A
- EPS Growth
- PYPD N/A
- CELU N/A
- EPS
- PYPD N/A
- CELU N/A
- Revenue
- PYPD N/A
- CELU $54,220,000.00
- Revenue This Year
- PYPD N/A
- CELU $23.29
- Revenue Next Year
- PYPD N/A
- CELU N/A
- P/E Ratio
- PYPD N/A
- CELU N/A
- Revenue Growth
- PYPD N/A
- CELU 138.11
- 52 Week Low
- PYPD $2.30
- CELU $1.00
- 52 Week High
- PYPD $4.42
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- PYPD 65.03
- CELU 71.05
- Support Level
- PYPD $3.30
- CELU $2.01
- Resistance Level
- PYPD $3.87
- CELU $2.66
- Average True Range (ATR)
- PYPD 0.14
- CELU 0.24
- MACD
- PYPD 0.01
- CELU 0.08
- Stochastic Oscillator
- PYPD 86.84
- CELU 91.67
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.